Literature DB >> 20628717

[Systemic lupus erythematosus. A problem based approach].

S Kleinert1, M Feuchtenberger, H-P Tony.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoinflammatory disease of unknown etiology with predominance of the female sex. Clinical criteria as well as immunological characteristics, e. g. autoantibodies, are necessary for diagnosis. The clinical course of SLE is variable and may be characterized by periods of remissions and chronic or acute relapses. New symptoms are often challenging regarding differential diagnosis. This review will discuss symptoms with a problem based approach. Parameters of activity are helpful to differentiate between disease activity and associated problems, e. g. infections. Lupus patients have a 5 times increased mortality compared to the normal population. The main reasons for mortality are infections and cardiovascular events, rather than disease manifestations. Therefore, besides the fast and precise use of immunosuppressants the consequent therapy of co-morbidities is a major issue in dealing with these patients. Cardiovascular risk factors need to be controlled, life style modifications should be started early, and diagnosis and therapy of osteoporosis should not be neglected.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20628717     DOI: 10.1007/s00108-010-2682-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  21 in total

Review 1.  [Pulmonary arterial hypertension in collagenoses].

Authors:  M Claussen; G Riemekasten; M M Hoeper
Journal:  Z Rheumatol       Date:  2009-10       Impact factor: 1.372

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2004-12

4.  Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data.

Authors:  R Ramsey-Goldman; J E Dunn; C F Huang; D Dunlop; J E Rairie; S Fitzgerald; S Manzi
Journal:  Arthritis Rheum       Date:  1999-05

Review 5.  The lung in the antiphospholipid syndrome.

Authors:  G Espinosa; R Cervera; J Font; R A Asherson
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

6.  Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection.

Authors:  R Brunkhorst; O K Eberhardt; M Haubitz; F M Brunkhorst
Journal:  Intensive Care Med       Date:  2000-03       Impact factor: 17.440

Review 7.  Systemic lupus erythematosus and cardiovascular disease.

Authors:  J Frostegård
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

8.  A screening strategy for population studies in systemic lupus erythematosus. Series design.

Authors:  M H Liang; R F Meenan; E S Cathcart; P H Schur
Journal:  Arthritis Rheum       Date:  1980-02

9.  Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort.

Authors:  S Durán-Barragán; G McGwin; L M Vilá; J D Reveille; G S Alarcón
Journal:  Rheumatology (Oxford)       Date:  2008-05-29       Impact factor: 7.580

10.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Authors:  G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

View more
  1 in total

Review 1.  The Diagnosis and Treatment of Systemic Lupus Erythematosus.

Authors:  Annegret Kuhn; Gisela Bonsmann; Hans-Joachim Anders; Peter Herzer; Klaus Tenbrock; Matthias Schneider
Journal:  Dtsch Arztebl Int       Date:  2015-06-19       Impact factor: 5.594

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.